ENTBF - Entheon Biomedical Corp.

Other OTC - Other OTC Delayed Price. Currency in USD
0.0170
-0.0003 (-1.57%)
At close: 03:00PM EDT
Stock chart is not supported by your current browser
Previous Close0.0173
Open0.0170
BidN/A x N/A
AskN/A x N/A
Day's Range0.0170 - 0.0170
52 Week Range0.0100 - 0.0810
Volume4,000
Avg. Volume5,280
Market Cap1.07M
Beta (5Y Monthly)1.80
PE Ratio (TTM)N/A
EPS (TTM)-0.0000
Earnings DateOct 28, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Ehave Shareholder from CEO Ben Kaplan and Corporate Update

    MIAMI, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Ehave, Inc., (OTC Pink: EHVVF) (the “Company”), a Healthcare Analytics provider with interests in the psychedelic and mental health sectors, today issued a letter to shareholders from its Chief Executive Officer, Ben Kaplan. Dear Fellow Shareholders As 2022 draws to a close, many of us will reflect on a year that saw global economic activity experiencing a broad-based and sharper-than-expected slowdown, increased inflation higher than we have seen in seve

  • Newsfile

    Entheon Announces Closing of Previously Announced Sale of Certain DMT Clinical Assets

    Vancouver, British Columbia--(Newsfile Corp. - July 11, 2022) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company") today announced that, further to its news release dated June 7, 2022, it has completed the sale of its Phase 1 N,N-dimethyltryptamine ("DMT") study (the "DMT Study") to Cybin IRL Limited (the "Purchaser"), a subsidiary of Cybin Inc. pursuant to an asset purchase agreement for a purchase price of CAD$1,000,000 (the "Transaction"). ...

  • Newsfile

    Entheon Announces Sale of Certain DMT Clinical Assets and Filing of Provisional Novel Compound Patents

    Vancouver, British Columbia--(Newsfile Corp. - June 7, 2022) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company") today announced that it has entered into a definitive agreement (the "Agreement") dated June 7, 2022 with Cybin IRL Limited (the "Purchaser"), a subsidiary of Cybin Inc. ("Cybin"), pursuant to which the Company has agreed to sell its Phase 1 N,N-dimethyltryptamine ("DMT") study (the "DMT Study") to the Purchaser (the "Transaction") for ...

  • GlobeNewswire

    Ehave, Inc. Announces Psychedelics Precision Medicine Platform For Clinical Research

    AI-driven discovery platform enables new way to find novel pathways, as well as progress towards identifying patients who may better respond to drugs in the clinicGenetic test kit evaluates an individual's overall sensitivity and risk profile associated with psychedelic-assisted therapy MIAMI, June 01, 2022 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a leading healthcare services and technology company, announced today its KetaDASH subsidiary will begin using precision med